V.TLT | December 9, 2024 Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites for clinical research of Theralase®’s bladder cancer treatment TORONTO, ON / December 9, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has launched three new US-based Clinical Study Sites (“CSSs“) for its bladder cancer registrational clinical study; specifically: Associated Medical Professionals of NY (Syracuse, New York), Urology of Indiana (Greenwood, Indiana) and Central Ohio Urology Group (Gahanna, Ohio). The Principal Investigators (“PIs“) for the Theralase® clinical study at the new CSSs are as follows: Associated Medical Professionals of NY – Ilija Aleksic, MD Dr. … Read More

V.TLT | December 5, 2024 St. Joseph’s Healthcare Hamilton is the latest Canadian clinical study site for clinical investigation of Theralase®’s Anti-Cancer Therapy for the treatment of bladder cancer TORONTO, ON / December 5, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has launched a new Clinical Study Site (“CSS“) for its bladder cancer clinical study; specifically, St. Joseph’s Healthcare Hamilton (Hamilton, Ontario, Canada). Theralase®’s lead drug, RuvidarTM (TLD-1433), activated by the TLC-3200 Medical Laser System (“TLC-3200“) is currently under clinical investigation in Canada and the United States in a Phase II registration study for Bacillus Calmette-Guérin (“BCG“)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC“) Carcinoma In-Situ (“CIS“) with or without resected … Read More

TORONTO, ON / November 27, 2024 / Theralase® Technologies Inc. (“ Theralase® ” or the “ Company “) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses has released the Company’s unaudited condensed consolidated interim financial statements for the nine-month period ended September 30, 2024. (“ Financial Statements “). Theralase® will be hosting a conference call on Wednesday December 4 th at 11:00 am ET , which will include a presentation of the financial and operational results for the nine-month period ended September 30, 2024. Questions are welcome. To ensure Theralase® has time to review and properly address them during the call, please send them in advance to mperraton@theralase.com . Zoom Meeting Link: https://us02web.zoom.us/j/84816819001 Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) – not required for those attending by Zoom. An archived version will be available on … Read More

TORONTO, ON / October 7, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it is providing an update on its bladder cancer clinical study. Theralase®’s lead drug, RuvidarTM, activated by the TLC-3200 Medical Laser System (“TLC-3200“) is currently under investigation in Canada and the United States in a Phase II registration study for Bacillus Calmette-Guérin (“BCG“)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC“) Carcinoma In-Situ (“CIS“) with or without resected Ta / T1 papillary disease (“Study II“). In the United States, an estimated 83,190 patients will be diagnosed with bladder cancer.1 Bladder cancer was the fourth leading cancer in men in 2023, representing 6% of estimated new cancers and 4% of cancer related deaths. … Read More

June 6, 2024 – Rutherrin®, has been proven effective preclinically in the destruction of Non-Small Cell Lung Cancer (“NSCLC”).

June 4, 2024 – Theralase’s lead compound, Ruvidar, has been proven effective in the inactivation of various viruses. The research was completed at the laboratory of Kevin Coombs, Ph.D., University of Manitoba in conjunction with National Microbiology Laboratory and Theralase® Technologies Inc.

May 30, 2024 – Theralase releases the Company’s unaudited interim consolidated 1Q2024 Financial Statements

May 2, 2024 – Theralase expands its clinical team with the hiring of two Clinical Research Associates.

April 5th, 2024, Theralase® granted Canadian patent for a new cancer vaccine titled, “Vaccine Containing Cancer Cells Inactivated by Photodynamic Treatment with Metal-Based Coordination Complexes and Immunotherapy Method Using Same”.

March 27, 2024 – Theralase released the Company’s audited annual consolidated 2023 financial statements (“Financial Statements”).